Portal Biotechnologies: Revolutionizing Cell Engineering with $5M Pre-Seed Funding
March 21, 2024, 9:34 pm
Portal Biotechnologies, a Cambridge-based cell engineering platform company, recently secured $5 million in pre-seed funding. Led by Pear VC, with contributions from Conscience VC and 10x Capital, this investment will fuel the company's mission to advance cell engineering technology for research and clinical applications.
Founded by Armon Sharei, Ph.D., the mastermind behind SQZ Biotechnologies, Portal Biotechnologies is taking a simplified approach to intracellular delivery. By focusing on RNA, gene editing, and AI-driven discovery technologies, Portal aims to accelerate scientific breakthroughs in cell modification.
The company's cutting-edge mechanical delivery technology can transport a variety of molecules into different cell types. By perturbing a cell's membrane as it passes through microscopic holes in a specially designed silicon surface, Portal enables the delivery of siRNA, mRNA, polypeptides, antibodies, and CRISPR RNP complexes. This multiplexed approach allows for precise cell function modification without altering the genome.
With over 20 active partners, including major pharmaceutical companies and academic institutions, Portal is expanding its reach in the biotech industry. The company's vision extends beyond its current offerings, as it plans to develop a suite of cell modification modules that can enhance cell functionality without genetic alterations.
Through partnerships with leading organizations and participation in accelerators like Bayer Co.Lab and the Roche Accelerator, Portal is poised to make a significant impact in the field of cell and gene therapy. By providing modular solutions for biological research, drug development, and cell therapy manufacturing, Portal aims to drive innovation and improve patient outcomes.
Armon Sharei, Founder and CEO of Portal Biotechnologies, expressed his gratitude for the support from investors and partners, emphasizing the company's commitment to overcoming challenges in the biotech industry. Eddie Eltoukhy, Partner at Pear VC, shared his excitement about joining forces with Portal to address critical issues in the field and potentially benefit countless patients.
With its innovative technology and strategic partnerships, Portal Biotechnologies is paving the way for groundbreaking advancements in cell engineering and therapeutic applications. As the company continues to grow and evolve, its impact on the biotech landscape is sure to be profound.
Founded by Armon Sharei, Ph.D., the mastermind behind SQZ Biotechnologies, Portal Biotechnologies is taking a simplified approach to intracellular delivery. By focusing on RNA, gene editing, and AI-driven discovery technologies, Portal aims to accelerate scientific breakthroughs in cell modification.
The company's cutting-edge mechanical delivery technology can transport a variety of molecules into different cell types. By perturbing a cell's membrane as it passes through microscopic holes in a specially designed silicon surface, Portal enables the delivery of siRNA, mRNA, polypeptides, antibodies, and CRISPR RNP complexes. This multiplexed approach allows for precise cell function modification without altering the genome.
With over 20 active partners, including major pharmaceutical companies and academic institutions, Portal is expanding its reach in the biotech industry. The company's vision extends beyond its current offerings, as it plans to develop a suite of cell modification modules that can enhance cell functionality without genetic alterations.
Through partnerships with leading organizations and participation in accelerators like Bayer Co.Lab and the Roche Accelerator, Portal is poised to make a significant impact in the field of cell and gene therapy. By providing modular solutions for biological research, drug development, and cell therapy manufacturing, Portal aims to drive innovation and improve patient outcomes.
Armon Sharei, Founder and CEO of Portal Biotechnologies, expressed his gratitude for the support from investors and partners, emphasizing the company's commitment to overcoming challenges in the biotech industry. Eddie Eltoukhy, Partner at Pear VC, shared his excitement about joining forces with Portal to address critical issues in the field and potentially benefit countless patients.
With its innovative technology and strategic partnerships, Portal Biotechnologies is paving the way for groundbreaking advancements in cell engineering and therapeutic applications. As the company continues to grow and evolve, its impact on the biotech landscape is sure to be profound.